A new review shows that Chinese pharmaceutical firms are racing ahead in the fight against brain disorders. In stroke research, two home‑grown multi‑target drugs—Nitronone (TBN) and the unique non‑peptide PSD95‑nNOS uncoupler Y‑3—have entered Phase III trials, with Y‑3 promising to block both the initial stroke damage and the depression that often follows. Alzheimer’s therapy is also moving fast: Hengrui’s anti‑Aβ antibody SHR‑1707 is the quickest‑advancing candidate in China, and the small‑molecule Octahydroaminoacridine succinate received market approval in August 2024 for mild‑to‑moderate disease. Depression pipelines include 28 candidates, among them DB104, a precision‑medicine breakthrough, and the multi‑target JJH‑201501 now in Phase III to tackle lingering symptoms and side‑effects of older antidepressants. In schizophrenia, the first Chinese‑developed mGluR2/3 modulator DB‑103 and Zai Lab’s KarXT (tropisetron chloride)—the first novel‑mechanism antipsychotic in 70 years—have been approved and entered national treatment guidelines. New insomnia options such as orexin‑blocker YZJ‑1139 are also in Phase III, showing better safety than traditional sleep drugs. Pain research focuses on non‑addictive solutions, with Nav1.8 inhibitors, anti‑NGF antibodies, and FM‑888—the world’s first central synaptic‑plasticity inhibitor—aiming to curb the opioid crisis. Overall, China’s pipeline now includes 5 drugs at NDA, 20 in Phase III, 87 in Phase II and 162 in early stages, shifting from classic targets to innovative areas like the brain‑gut axis, ion channels and novel receptors, and embracing multi‑target strategies to address complex neuropsychiatric conditions.
Read moreA wave of breakthroughs is reshaping how doctors fight leukemia. Researchers have decoded how abnormal RNA splicing creates unique “neo‑antigens” that can be recognized by engineered T‑cell receptors, paving the way for highly specific TCR‑T cell therapies for myeloid cancers. Meanwhile, a massive epidemiological study led by Academician Huang Xiaojun mapped leukemia’s rise in China from 2000‑2022, revealing shifting patterns, treatment gains, and looming challenges. In a paradigm‑shifting Nature paper, scientists showed that a by‑product of V(D)J recombination can replicate itself, potentially sparking disease relapse and forcing a rethink of diagnostic strategies. MD Anderson’s latest review highlights cutting‑edge drugs and combination regimens that are already extending patient survival. On the technology front, a team created calcium‑carbonate nanoparticles cloaked in cell‑membrane material that simultaneously deliver asparaginase and metformin directly to bone‑marrow tumors, dramatically slowing growth in animal models. A separate Nature report uncovered that bone‑marrow stromal cells act like an “energy drink,” pumping taurine into leukemia stem cells via the TAUT transporter, which fuels their metabolism and growth—offering a fresh drug target. Finally, a new clinical‑trial chip enables real‑time monitoring of CAR‑T cell activity, helping doctors fine‑tune immunotherapy on the fly. Together, these advances promise more precise, less toxic, and ultimately more effective leukemia treatments.
Read moreThe International Stroke Conference 2026 showcased a host of advances that could change how patients recover from brain attacks. A Chinese Phase III trial highlighted Loberamusal, a novel neuroprotective compound that helped stroke survivors regain function faster than standard care, sparking hope for a new class of rehabilitation drugs. In a separate study, giving recombinant coagulation factor VIIa within two hours of a brain bleed slowed the growth of the hematoma, but it did not translate into better long‑term outcomes and raised a small risk of dangerous clots. Researchers from Beijing Tiantan Hospital presented a suite of precision‑medicine tools: refined criteria for selecting patients for clot‑removing procedures, personalized antiplatelet regimens, neuromodulation‑assisted therapy, and cutting‑edge imaging that pinpoints micro‑circulation problems and language‑area damage. Sun Yat‑sen Memorial Hospital added new data on endovascular stroke treatment, aneurysm management, and molecular pathways that protect brain tissue. A CREST‑2 sub‑analysis found that neither surgery nor stenting improved cognition in people with silent carotid narrowing. Beijing Union Medical College Hospital offered a multidimensional look at intracranial atherosclerosis, linking genetics, glymphatic dysfunction, and novel PCSK9 inhibitors to stroke risk. Finally, the OCEANIC‑STROKE trial showed that the factor XIa inhibitor asundexian cuts recurrent ischemic stroke risk without extra bleeding, while the CHOICE2 study demonstrated that a small dose of intra‑arterial alteplase after successful thrombectomy boosts functional recovery. Together, these findings point toward safer, more tailored, and more effective stroke care for patients worldwide.
Read more